Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-03-13
2007-03-13
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388800, C530S388850, C530S388150, C530S391500, C530S391700, C424S130100, C424S133100, C424S156100, C424S179100, C424S183100
Reexamination Certificate
active
10088639
ABSTRACT:
An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23–33 (CDR1), 49–55 (CDR2), 88–98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158–162 (CDR1), 177–193 (CDR2, 226–238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.
REFERENCES:
patent: 5320942 (1994-06-01), Quaranta et al.
patent: 6113898 (2000-09-01), Anderson et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 0 537 654 (1993-04-01), None
patent: 2305921 (1997-04-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 99/06834 (1999-02-01), None
Fernsten et al Cancer Research 51:926-934, 1991.
Ezzell (J. NIH Res, 1995, 7:46-49.
Spitler (Cancer Biotherapy, 1995, 10:1-3.
Boon (Adv Can Res, 1992, 58:177-210.
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer (Bio/Technology, 1994, 12:320.
Gura (Science, 1997, 278:1041-1042.
Rudlkoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Schwartz et al, Proc Natl Acad Sci USA vol. 84:6408-6411 (1987).
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252,
Lin et al Biochemistry USA vol. 14:1559-1563 (1975).
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79 p. 1979).
Colman et al (Research in Immunology 1994, 145:33-36).
Jerome Decosse et al., “Colorectal Cancer: Detection, Treatment, and Rehabilitation.” CA Cancer J. Clin, vol. 44, No. 1, Jan./Feb. 1994, pp. 27-42. American Cancer Society, Atlanta, GA.
G. Riethmüller et al., “Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized trial.”Journal of Clinical Oncology, vol. 16, No. 5 May, 1998, pp. 1788-1794. American Society of Clinical Oncology, Alexandria, VA.
Joseph A. Kuhn et al. “Monoclonal Antibodies and Colorectal Carcinoma: A Clinical Review of Diagnostic Applications.”Cancer Investigation, 12(3), 1994, pp. 314-323. Marcel Dekker, Inc., New York, NY.
Jesper Tordsson et al., “Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue sections.”Journal of Immunological Methods, 210 (1997), pp. 11-23. North Holland Publishing, Amsterdam, Holland.
L. Aujame et al., “High affinity human antibodies by phage display.”Human Antibodies, 1997, vol. 8, 4, pp. 155-168. IOS Press, Amsterdam, Holland.
Robert K. Clark, et al., “Immunohistochemical Analysis of Antiserum from Rhesus Monkeys Immunized with Human Colon Carcinoma.”Cancer Research, 49, Jul. 1, 1989, pp. 3656-3661. American Association for Cancer Research, Baltimore, MD.
Alan P. Lewis, et al. “Cloning and Sequence Analysis of κ and γ Cynomolgus Monkey Immunoglobulin cDNAs,”Developmental and Comparative Immunology, vol. 17, 1993, pp. 549-560. Pergamon Press Ltd., Oxford, UK.
Thomas N. Brodin et al. “Man-made superantigens: Tumor-selective agents for T-cell-based therapy.”Advanced Drug Delivery Reviews31 (1998) pp. 131-142). Elsevier Science B.V., Amsterdam, Holland.
Mikael Dohlsten et al., “Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell-based tumor therapy.”Proc. Natl. Acad. Sci USA, vol. 91,, Sep. 1994, Immunology, pp. 8945-8949. National Academy of Sciences, Washington, D.C.
Changnian Liu, et al., “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids,”Proc. Natl. Acad. Sci USA,vol. 93, Aug. 1996, Medical Sciences, pp. 8618-8623, National Academy of Sciences, Washington, D.C.
Garzino-Demo et al., “Altered expression of α6 integrin subunit in oral squamous cell carcinoma and oral potentially malignant lesions”,Oral Oncology, 34 (1998), pp. 204-210.
Hogervorst et al., “Biochemical Characterization and Tissue Distribution of the A and B Variants of the Integrin α6 Subunit”,The Journal of Cell Biology, vol. 121, Apr. 1993, pp. 179-191.
Tennenbaum et al., “A splice variant of α6 integrin is associated with malignant conversion in mouse skin tumorigenesis”,Proc. Natl. Acad. Sci. USA,vol. 92, Jul. 1995, pp. 7041-7045.
Weinel et al., “The α6-Integrin Receptor in Pancreatic Carcinoma”,Gastroenterology, 1995, 108: 523-532.
Pulkkinen et al., “Novel ITGB4 Mutations in Lethal and Nonlethal Variants of Epidermolysis Bullosa with Pyloric Atresia: Missense versus Nonsense”,Am. J. Hum. Genet.,63: 1376-3787 (1998).
Chao et al., “A Function for the Integrin α6β4in the Invasive Properties of Colorectal Carcinoma Cells”,Cancer Research, 56, 4811-4819, Oct. 15, 1996.
Rabinovitz et al., “The Integrin α6β4 and the Biology of Carcinoma”,Biochem. Cell Biol.,74:811-821 (1996).
Koretz et al., “Comparative evaluation of Integrin α- β-chain expression in colorectal carcinoma cell lines and in their tumors of origin”,Virchows Archiv,(1994) 425-429—236.
Mimori et al., “Clinical significance of integrin α6 mRNA expression in gastric carcinoma”,International Journal of Oncology, 11: 959-964, (1997).
Patriarca et al., “VLA-alpha-3 and VLA-alpha-6 integrins may lack the cytoplasmic domain in colon adenocarcinomas: An immunocytochemical and RT-PCR study”,Modern Pathology, vol. 8, No. 1, 1995, p. 66A.
Oxford Dictionary of Biochemistry and Molecular Biology, 1997, p. 165, Oxford University Press, New York.
Dohlsten et al., “Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell based tumor therapy”, Proc. Natl. Acad. Sci. USA, Sep. 1994, vol. 91, pp. 8945-8949, Pharmacia Oncology Immunology, Lund, Sweden.
Brodin Thomas
Karlström Pia J.
Kearney Philip P.
Nilson Bo H. K.
Ohlsson Lennart G.
Active Biotech AB
Buchanan & Ingersoll & Rooney PC
Helms Larry R.
Tungaturthi Parithosh K.
LandOfFree
Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3757190